AC Immune SA ACIU
2.13 USD +0.06 (+3.16%)
Nov 3, 2026, 3:21 PM EST
2.06 Day range 2.16
2.02 52-week range 3.90
- YTD
- -32.32%
- 1 year
- -33.18%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 10.01 +370.9% upside
Now 2.13
- Target (low)
- 7.54
- Target (mean)
- 10.01
- Target (high)
- 15.77
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy1
- Buy3
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 4
- 1 month ago 4
- 2 months ago 4
- 3 months ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.187 | -0.201 – -0.17 | -0.05 | -274.0% | 556.43K | -96.2% | 3 |
| Next quarter | 0.00 | 0.00 – 0.00 | -0.18 | 0.0% | 0 | 0.0% | 0 |
| Current year | -0.536 | -0.552 – -0.52 | -0.64 | +16.3% | 26.79M | +81.0% | 2 |
| Next year | -0.03033 | -0.75 – 0.359 | -0.536 | +94.3% | 61.61M | +130.0% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 6, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 18, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 31, 2024 | BTIG | Initiated | — | Buy |
| Mar 15, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 13, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 7, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 28, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 1, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Apr 19, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Mar 17, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Jul 11, 2022 | SVB Leerink | Maintained | — | Outperform |
| Dec 20, 2021 | SVB Leerink | Maintained | — | Outperform |
| Mar 24, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Dec 10, 2019 | HC Wainwright & Co. | Reiterated | — | Buy |
| Feb 1, 2019 | UBS | Downgrade | Buy | Neutral |
| Nov 13, 2018 | Leerink Swann | Initiated | — | Outperform |
| Apr 5, 2018 | HC Wainwright & Co. | Initiated | — | Buy |
| Oct 18, 2016 | Leerink Swann | Initiated | — | Outperform |
